Zevia (NYSE:ZVIA) reported quarterly sales of $45.50 million which beat the analyst consensus estimate of $42.17 million by 7.90 percent. This is a 32.45 percent increase over sales of $34.35 million the same period last year.
60 Degrees Pharmaceuticals Announces FDA Orphan Drug Designation For Tafenoquine To Treat Acute Babesiosis
With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees.60
